Thermo Fisher Scientific Inc (TMO) Stock Rating Reaffirmed by Barclays PLC

Thermo Fisher Scientific Inc (NYSE:TMO)‘s stock had its “overweight” rating reissued by stock analysts at Barclays PLC in a note issued to investors on Tuesday, May 9th, MarketBeat reports. They currently have a $190.00 target price on the medical research company’s stock, up from their previous target price of $175.00. Barclays PLC’s price target suggests a potential upside of 8.84% from the stock’s previous close.

Several other analysts have also recently commented on the stock. Evercore ISI upped their target price on shares of Thermo Fisher Scientific from $160.00 to $162.00 and gave the company a “buy” rating in a research report on Tuesday, January 31st. Jefferies Group LLC lowered their price objective on shares of Thermo Fisher Scientific from $163.00 to $160.00 and set a “hold” rating for the company in a research report on Monday, January 23rd. Deutsche Bank AG restated a “buy” rating and issued a $163.00 price objective on shares of Thermo Fisher Scientific in a research report on Wednesday, January 18th. Cowen and Company restated an “outperform” rating and issued a $185.00 price objective (up previously from $175.00) on shares of Thermo Fisher Scientific in a research report on Saturday, April 29th. Finally, Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “sell” rating to a “hold” rating in a research report on Monday, February 13th. Three investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. Thermo Fisher Scientific has an average rating of “Buy” and a consensus price target of $183.47.

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Shares of Thermo Fisher Scientific (NYSE TMO) traded down 0.21% during trading on Tuesday, hitting $174.57. The stock had a trading volume of 1,337,309 shares. The stock’s 50 day moving average is $171.99 and its 200 day moving average is $156.01. Thermo Fisher Scientific has a 52 week low of $139.07 and a 52 week high of $176.85. The stock has a market capitalization of $68.30 billion, a price-to-earnings ratio of 31.84 and a beta of 1.05.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, April 26th. The medical research company reported $2.08 earnings per share for the quarter, topping the consensus estimate of $2.02 by $0.06. Thermo Fisher Scientific had a net margin of 11.58% and a return on equity of 15.73%. The firm had revenue of $4.77 billion during the quarter, compared to analysts’ expectations of $4.68 billion. During the same quarter in the previous year, the company posted $1.80 EPS. Thermo Fisher Scientific’s revenue was up 10.9% on a year-over-year basis. On average, equities research analysts expect that Thermo Fisher Scientific will post $9.22 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, July 17th. Shareholders of record on Thursday, June 15th will be issued a $0.15 dividend. The ex-dividend date of this dividend is Tuesday, June 13th. This represents a $0.60 annualized dividend and a yield of 0.34%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.95%.

COPYRIGHT VIOLATION NOTICE: “Thermo Fisher Scientific Inc (TMO) Stock Rating Reaffirmed by Barclays PLC” was published by Community Financial News and is the property of of Community Financial News. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.com-unik.info/2017/06/15/thermo-fisher-scientific-inc-tmo-receives-overweight-rating-from-barclays-plc-updated-updated-updated.html.

In other news, CEO Marc N. Casper sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $172.79, for a total transaction of $3,455,800.00. Following the transaction, the chief executive officer now directly owns 269,279 shares of the company’s stock, valued at $46,528,718.41. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Stephen Williamson sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $176.26, for a total transaction of $440,650.00. Following the transaction, the chief financial officer now directly owns 37,790 shares in the company, valued at $6,660,865.40. The disclosure for this sale can be found here. Over the last three months, insiders sold 28,720 shares of company stock worth $4,960,764. Insiders own 0.49% of the company’s stock.

Several hedge funds have recently bought and sold shares of TMO. Clearbridge Investments LLC raised its stake in Thermo Fisher Scientific by 16.6% in the first quarter. Clearbridge Investments LLC now owns 2,571,783 shares of the medical research company’s stock valued at $395,026,000 after buying an additional 365,409 shares in the last quarter. Perigon Wealth Management LLC raised its stake in Thermo Fisher Scientific by 2.1% in the first quarter. Perigon Wealth Management LLC now owns 30,854 shares of the medical research company’s stock valued at $4,744,000 after buying an additional 624 shares in the last quarter. Piedmont Investment Advisors LLC raised its stake in shares of Thermo Fisher Scientific by 0.9% in the first quarter. Piedmont Investment Advisors LLC now owns 83,285 shares of the medical research company’s stock worth $12,793,000 after buying an additional 707 shares in the last quarter. Skandinaviska Enskilda Banken AB publ raised its stake in shares of Thermo Fisher Scientific by 1.5% in the first quarter. Skandinaviska Enskilda Banken AB publ now owns 63,315 shares of the medical research company’s stock worth $9,725,000 after buying an additional 930 shares in the last quarter. Finally, HM Payson & Co. raised its stake in shares of Thermo Fisher Scientific by 55.4% in the first quarter. HM Payson & Co. now owns 10,665 shares of the medical research company’s stock worth $1,638,000 after buying an additional 3,800 shares in the last quarter. Institutional investors and hedge funds own 86.89% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

What are top analysts saying about Thermo Fisher Scientific Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Thermo Fisher Scientific Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit